Trial Profile
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of Apremilast (CC-10004) in subjects with active psoriatic arthritis who have not been previously treated with disease-modifying antirheumatic drugs
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jan 2024
Price :
$35
*
At a glance
- Drugs Apremilast (Primary)
- Indications Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms PALACE-4
- Sponsors Celgene Corporation
- 15 Nov 2023 Results assessing the effects of apremilast on cardiometabolic parameters over 52 weeks in patients with active psoriatic arthritis from 5 studies PALACE 1-4 and ACTIVE, presented at the ACR Convergence 2023.
- 03 Jun 2023 Results of pooled analysis (n=781 from studies PALACE 1 to 4 and ACTIVE) assessing the effects of APR on cardiometabolic parameters over 52 weeks in patients with active psoriatic arthritis presented at the 24th Annual Congress of the European League Against Rheumatism
- 30 May 2023 Results presented in an Amgen Media Release.